Higher compared with lower dietary protein during an energy deficit combined with intense exercise promotes greater lean mass gain and fat mass loss
Food and Drug Administration (FDA), the approved dosages for some of the commonly prescribed GLP-1 agonists are as follows: Semaglutide (Ozempic): 0.5 mg, 1 mg, or 2 mg once weekly for type 2 diabetes, and up to 2.4 mg once weekly for chronic weight management (marketed as Wegovy)
Beginning in April 2026, Medicare will also cover GLP-1 medications for beneficiaries with obesity and qualifying comorbidities
This does not go through insurance, but many patients find it more affordable than their insurance copays for brand medications, particularly given Californias high cost of living and the variability in employer health plan coverage for weight loss drugs
Zheng J, Lu J, Qi J, Yang Q, Zhao H, Liu H, Chen Z, Huang L, Ye Y, Xu M
In contrast, Zepbound (tirzepatide) is emerging as the fastest-growing product
